Adverse events (hospital records/every 6 weeks) · asymptomatic carotid stenosis
Lipid‐lowering agent showed no clear difference in adverse events (only reported for two studies: one study used CT… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Serious adverse events "Defined as events that result in death, hospitalization, prolongation of hospitalization, or are life threatening (based on the judgment of the study physician)" (Quinn 2010) · Apathy in people with mild‐to‐moderate Alzheimer's disease
Omega‐3 PUFA supplements showed no clear difference in serious adverse events "Defined as events that result in death,… compared with placebo (high certainty).
1 finding from 1 review
Adverse events (control ‐ deferred treatment) · patients with first unprovoked seizure
Immediate treatment probably leads to higher adverse events (control ‐ deferred treatment) compared with controls (moderate certainty).
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Non‐serious adverse events (secondary outcome) · prevention and treatment of hepatic encephalopathy in people with cirrhosis
It is very uncertain whether lactulose changes non‐serious adverse events (secondary outcome) compared with lactitol (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who reported adverse events · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who reported adverse events (very low certainty).
1 finding from 1 review
Adverse events (number of participants with any adverse event) · adult participants, irrespective of gender and type of non‐cardiac surgery, with mild or severe preoperative anaemia
rHuEPO with iron showed no clear difference in adverse events (number of participants with any adverse event) compared with control treatment with or without iron (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events ( · Patients between three and 12 years old with clinical and EEG diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (28 weeks trial period) · Patients between five and 15 years old with a diagnosis of BECTS
The intervention showed no clear difference in proportion of patients who discontinued treatment due to adverse… (low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (96 weeks trial period) · Patients with a clinical and EEG diagnosis of BECTS
It is very uncertain whether the intervention changes proportion of patients who discontinued treatment due to adverse… (very low certainty).
1 finding from 1 review
Intervention not reported
Proportion of patients who discontinued treatment due to adverse events (over 6 months trial period) · Patients between three and 10 years old with a diagnosis of BECTS
1 finding from 1 review